SUVEN LIFE SCIENCES LIMITED Suven Life Sciences Limited Stock NSE India S.E.
Equities
SUVEN
INE495B01038
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 106.2 INR | -3.50% |
|
-8.96% | +31.46% |
| Sales 2022 | 120M 1.43M | Sales 2023 | 136M 1.63M | Capitalization | 10.57B 127M |
|---|---|---|---|---|---|
| Net income 2022 | -1.22B -14.62M | Net income 2023 | -1.18B -14.17M | EV / Sales 2022 | 109 x |
| Net cash position 2022 | 472M 5.66M | Net cash position 2023 | 2.27B 27.17M | EV / Sales 2023 | 61.1 x |
| P/E ratio 2022 |
-9.69
x | P/E ratio 2023 |
-7.31
x | Employees | 132 |
| Yield 2022 |
1.08% | Yield 2023 |
-
| Free-Float | 28.95% |
More Fundamentals
* Assessed data
More news
Latest transcript on Suven Life Sciences Limited
More press releases
| 1 day | -3.50% | ||
| 1 week | -8.96% | ||
| Current month | +6.15% | ||
| 1 month | +2.61% | ||
| 3 months | -6.72% | ||
| 6 months | +47.94% | ||
| Current year | +31.46% |
1 week
105.00
118.00
1 month
96.00121.50
Current year
82.15129.00
1 year
55.10129.00
3 years
45.00129.00
5 years
15.20334.70
10 years
15.20338.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 74 | 89-03-08 | |
M. Mohan Kumar
DFI | Director of Finance/CFO | - | 20-01-09 |
Shrenik Soni
CMP | Compliance Officer | - | 20-01-09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 74 | 89-03-08 | |
Sudha Rani Jasti
FOU | Founder | 70 | 89-03-08 |
| Director/Board Member | 70 | 10-04-29 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 106.2 | -3.50% | 296 114 |
| 24-04-18 | 110 | -1.65% | 140,370 |
| 24-04-16 | 111.8 | -0.09% | 119,525 |
| 24-04-15 | 112 | -3.24% | 198,565 |
| 24-04-12 | 115.7 | -0.77% | 139,040 |
Delayed Quote NSE India S.E., April 19, 2024 at 07:43 am EDT
More quotes
Suven Life Sciences Limited is an India-based biopharmaceutical company. The Company is engaged in the drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs, globally. It operates through the research and development services segment. Its drug discovery & research/clinical pipeline include Masupirdine (SUVN-502) Neuropsychiatric Symptoms in Alzheimer's, Masupirdine (SUVN-502) Cognitive deficits in AD, Samelisant (SUVN-G3031) Narcolepsy, Samelisant (SUVN-G3031) Cognitive Disorders, Ropanicant (SUVN-911) Depressive Disorders, Usmarapride (SUVN-D4010), Cognitive Disorders, SUVN-I6107, Cognitive Disorders and Schizophrenia, SUVN-M8036, Psychiatric Disorders, and SUVN-D1044 Gastrointestinal Disorders. Its drug discovery & development support services (DDDSS) include synthetic and medicinal chemistry, analytical chemistry, in vitro biology, ADME, pharmacology, toxicology, bioanalysis, and NCE formulations.
Calendar
2024-05-01
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -1.94% | 41.35B | |
| +42.15% | 40.38B | |
| +1.76% | 39.05B | |
| -14.19% | 26.67B | |
| +1.67% | 24.07B | |
| -23.81% | 18.36B | |
| -3.93% | 11.68B | |
| +20.98% | 11.6B | |
| +7.55% | 11.15B |
- Stock Market
- Equities
- SUVEN Stock
- SUVEN Stock
